Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2012 1
2019 2
2021 4
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.
Stukalov A, Girault V, Grass V, Karayel O, Bergant V, Urban C, Haas DA, Huang Y, Oubraham L, Wang A, Hamad MS, Piras A, Hansen FM, Tanzer MC, Paron I, Zinzula L, Engleitner T, Reinecke M, Lavacca TM, Ehmann R, Wölfel R, Jores J, Kuster B, Protzer U, Rad R, Ziebuhr J, Thiel V, Scaturro P, Mann M, Pichlmair A. Stukalov A, et al. Among authors: bergant v. Nature. 2021 Jun;594(7862):246-252. doi: 10.1038/s41586-021-03493-4. Epub 2021 Apr 12. Nature. 2021. PMID: 33845483
The alternative cap-binding complex is required for antiviral defense in vivo.
Gebhardt A, Bergant V, Schnepf D, Moser M, Meiler A, Togbe D, Mackowiak C, Reinert LS, Paludan SR, Ryffel B, Stukalov A, Staeheli P, Pichlmair A. Gebhardt A, et al. Among authors: bergant v. PLoS Pathog. 2019 Dec 19;15(12):e1008155. doi: 10.1371/journal.ppat.1008155. eCollection 2019 Dec. PLoS Pathog. 2019. PMID: 31856218 Free PMC article.
Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2'-O-ribose methyltransferases.
Bergant V, Yamada S, Grass V, Tsukamoto Y, Lavacca T, Krey K, Mühlhofer MT, Wittmann S, Ensser A, Herrmann A, Vom Hemdt A, Tomita Y, Matsuyama S, Hirokawa T, Huang Y, Piras A, Jakwerth CA, Oelsner M, Thieme S, Graf A, Krebs S, Blum H, Kümmerer BM, Stukalov A, Schmidt-Weber CB, Igarashi M, Gramberg T, Pichlmair A, Kato H. Bergant V, et al. EMBO J. 2022 Sep 1;41(17):e111608. doi: 10.15252/embj.2022111608. Epub 2022 Jul 25. EMBO J. 2022. PMID: 35833542 Free PMC article.
Engineered, nucleocytoplasmic shuttling Cas13d enables highly efficient cytosolic RNA targeting.
Gruber C, Krautner L, Bergant V, Grass V, Ma Z, Rheinemann L, Krus A, Reinhardt F, Mazneykova L, Rocha-Hasler M, Truong DJ, Westmeyer GG, Pichlmair A, Ebert G, Giesert F, Wurst W. Gruber C, et al. Among authors: bergant v. Cell Discov. 2024 Apr 12;10(1):42. doi: 10.1038/s41421-024-00672-1. Cell Discov. 2024. PMID: 38609360 Free PMC article. No abstract available.
A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response.
Lainšček D, Fink T, Forstnerič V, Hafner-Bratkovič I, Orehek S, Strmšek Ž, Manček-Keber M, Pečan P, Esih H, Malenšek Š, Aupič J, Dekleva P, Plaper T, Vidmar S, Kadunc L, Benčina M, Omersa N, Anderluh G, Pojer F, Lau K, Hacker D, Correia BE, Peterhoff D, Wagner R, Bergant V, Herrmann A, Pichlmair A, Jerala R. Lainšček D, et al. Among authors: bergant v. Vaccines (Basel). 2021 Apr 27;9(5):431. doi: 10.3390/vaccines9050431. Vaccines (Basel). 2021. PMID: 33925446 Free PMC article.
Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs.
Manček-Keber M, Hafner-Bratkovič I, Lainšček D, Benčina M, Govednik T, Orehek S, Plaper T, Jazbec V, Bergant V, Grass V, Pichlmair A, Jerala R. Manček-Keber M, et al. Among authors: bergant v. FASEB J. 2021 Jun;35(6):e21651. doi: 10.1096/fj.202100560R. FASEB J. 2021. PMID: 34004056 Free PMC article.
12 results